abstract BACKGROUND: Knobloch syndrome is a rare, autosomal recessive, developmental disorder characterized by stereotyped ocular abnormalities with or without occipital skull deformities (encephalocele, bone defects, and cutis aplasia). Although there is clear heterogeneity in clinical presentation, central nervous system malformations, aside from the characteristic encephalocele, have not typically been considered a component of the disease phenotype. METHODS: Four patients originally presented for genetic evaluation of symptomatic structural brain malformations. Whole-genome genotyping, whole-exome sequencing, and confirmatory Sanger sequencing were performed. Using immunohistochemical analysis, we investigated the protein expression pattern of COL18A1 in the mid-fetal and adult human cerebral cortex and then analyzed the spatial and temporal changes in the expression pattern of COL18A1 during human cortical development using the Human Brain Transcriptome
Introduction
First described by Knobloch and Layer in 1971, 1 Knobloch syndrome (OMIM: #267750, #608454) is a rare autosomal recessive syndrome characterized by stereotyped ocular abnormalities with or without occipital skull abnormalities. Ocular conditions traditionally include high myopia, lens subluxation, vitreoretinal degeneration, retinal detachment, and early-onset cataracts; occipital skull abnormalities can include encephalocele, bone defects, or cutis aplasia. Since the original report, at least 85 cases of Knobloch syndrome from 44 families have been described, each with varying degrees of clinical heterogeneity. [2] [3] [4] [5] In 2000, Sertie et al. 6 identified COL18A1 (OMIM *120328) as the disease-causing gene for Knobloch syndrome by performing linkage analysis in a large consanguineous family. The authors discovered a homozygous acceptor splice site mutation affecting the gene product of COL18A1. Since this original report, numerous mutations in COL18A1 have been identified in unrelated families who have Knobloch syndrome, thus confirming its causal relation with the syndrome. 7 To date, more than 21 different mutations have been described in patients from various ethnicities. [4] [5] [6] [8] [9] [10] [11] [12] In addition to the characteristic ocular and occipital skull defects, Knobloch syndrome can present with a spectrum of phenotypic findingsdsome patients have presented with lung hypoplasia, hyperextensible joints, duplication of the renal collecting system, epilepsy, neuronal migration abnormalities, and dysmorphic findings such as midface hypoplasia, flat nasal bridge, dental abnormalities, higharched palate, or micrognathia. 10, 13 Although neuronal migratory abnormalities and brain malformations have been previously reported in the literature (a total of seven patients from four case series, Table 1) , 3, 9, 10, 14 central nervous system malformations (aside from the characteristic encephalocele) have been considered relatively rare and have not traditionally been considered a hallmark feature of Knobloch syndrome. Here we describe four patients with structural brain malformations (with or without encephaloceles) who were found to possess frame-shift homozygous mutations in COL18A1 via whole-exome and Sanger sequencing. When we further investigated these patients and their families, we discovered that these patients possessed some of the characteristic phenotypic features of Knobloch syndrome.
Materials and Methods

Participants
The study protocol was approved by the Yale Human Investigation Committee (protocol number 0908005592). Institutional review board approvals for genetic and magnetic resonance imaging studies, along with written consent from all study participants, were obtained by the referring physicians at the participating institutions. All fetal human tissues were collected under guidelines approved by the Yale Human Investigation Committee (protocol number 0605001466).
Human fetal brains at 20 and 22 weeks of gestation were obtained from the Human Fetal Tissue Repository at the Albert Einstein College of Medicine (CCI number 1993-042).
Genome-wide genotyping
Samples were analyzed using an Omni 1M Quad V1-0 B SNP chip and 610K Quad Bead Chips according to the manufacturer's protocol (Illumina).
Exome capture and sequencing
NimbleGen 2.1M human exome array (Roche Nimblegen, Inc) was used to capture the exomes of all samples according to the manufacturer's protocol with certain modifications, as described previously. 15 Sequencing of the library was performed on HiSeq 2000 using a barcoding technology allowing for six samples per lane. The Illumina pipeline version 1.8 was used for image analysis and base calling. These methods were previously described in detail. 16 
Exome data analysis
Analysis of the sequencing data was performed according to the previously described in-house written data analysis pipeline. 17 Briefly, we used sequence reads that passed Illumina quality filter for analyzing whole-exome data. We aligned reads to the human genome reference sequence (version GRCh37, the same as used in the phase 1 of 1000 Genomes Project) using Stampy (version 1.0.16) 18 in a hybrid mode with BWA (version 0.5.9-r16). 19 We detected variant sites (point mutations and small indels) using the Unified Genotyper algorithm from GATK. 20 We annotated variant alleles using Ensembl database (version 66) with the help of Variant Effect Predictor (v2.4) tool (http://useast.ensembl. org/info/docs/variation/vep/vep_script.html).
Sanger sequencing
Coding regions and exon-intron boundaries of COL18A1 were evaluated via Sanger sequencing using standard protocols. Amplicons were cycle sequenced on ABI 9800 Fast Thermocyclers, and post-cycle sequencing cleanup was carried out with CleanSEQ System (Beckman Coulter Genomics). The amplicons were analyzed on 3730ÂL DNA Analyzer (Applied Biosystems Inc).
Immunohistochemistry
Cortices from human fetal brain (20 weeks after conception) were fixed in 4% paraformaldyhyde and cut into sections using a vibratome. Free-floating sections were preincubated in 1% hydrogen peroxide solution (T.J. Baker) at room temperature for 20 minutes and recovered in phosphate-buffered saline (PBS). Sections were then preblocked in blocking solution containing 5% normal donkey serum (Jackson Immuno Research Laboratories), 1% bovine serum albumin, 0.1% glycine, 0.1% lysine, and 0.3% Triton X-100 in PBS for 1 hour at room temperature. After preblocking, sections were incubated in anti-human endostatin (goat, 1:40; AF1098; R&D Systems) diluted in blocking solution on a horizontal shaker at 4 C for 48 hours and then washed in PBS at room temperature to remove excessive primary antibody. Sections were then incubated with biotinylated secondary antibody (Donkey Anti-Goat IgG; Jackson ImmunoResearch) diluted in blocking solution for 2 hours at room temperature. After washing in PBS, sections were further incubated in avidin-biotinperoxidase complex (Vectastain ABC Elite Kit; Vector Laboratories) for 1 hour at room temperature and washed three times in PBS. Peroxidase activity was developed using a DAB peroxidase substrate kit (Vector Laboratories). Sections were mounted on Superfrost Plus charged slides (Fisher Scientific), allowed to air dry, and then were coverslipped with Permount (Fisher Scientific) for later examination and imaging.
Results
Patient descriptions
Four patients, two boys and two girls, with a median age of 13.5 years (range, 13e22 years), and their parents and siblings from four distinct consanguineous Turkish families (NG133, NG1348, NG1426, and NG159) were enrolled in our study in accordance with the policies of and following the approval by our institutional review board ( Supplementary  Fig 1) . These four patients originally presented for genetic evaluation of symptomatic structural brain malformations. All four patients were confirmed to have structural brain malformations and various ocular abnormalities (Table 2) . Representative magnetic resonance imaging findings from these patients are shown in Fig 1. Genotyping and whole-exome sequencing DNA was extracted from the blood samples from the four patients and their parents and siblings. Whole-genome genotyping was performed for three of these four families (NG133, NG1348, and NG1426) and identified shared homozygous segments (each >2.5 cM) and revealed an index of homozygosity consistent with a consanguineous union in each of these three families. We then performed wholeexome sequencing using NimbleGen SeqCap EZ and the Illumina HiSeq 2000 on the index patients from each of these three families (as previously described). 16 We achieved mean 20Â coverage of 87%, 82%, and 84% for NG133-1, NG1348-1, and NG1426-1, respectively, of all targeted bases (Supplementary Table 1 ). This coverage was more than sufficient to identify homozygous variants with a high Fig 1, and Supplementary Fig 2) .
14 All variants were confirmed as homozygous in the affected patients and heterozygous in their respective parents via Sanger sequencing (Supplementary Fig 3) . DNA extracted from Patient NG159-2's blood underwent Sanger screening for the exons of COL18A1 and was found to harbor the homozygous c.4768_4769delCT mutation (p.Leu1590-ValfsX72). Like the other patients, NG159-2's parents were heterozygous for this variant (Supplementary Fig 4) .
For two of the three patients who underwent whole-exome sequencing, we identified no other known disease-causing mutations that may have been responsible for their phenotypes. In Patient NG1348-1, we found a nonconserved missense mutation in PCNT in addition to the COL18A1 mutation (Supplementary Table 3 ). However, although the mutation in PCNT may be contributing to the phenotype, we believe that it is the COL18A1 mutation that is predominantly responsible for abnormalities identified in this patient.
COL18A1 expression in the developing brain
To better understand the potential for mutations in COL18A1 to contribute to the pathogenesis of central nervous system malformations in these patients, we assessed the extent to which COL18A1 was expressed in the developing 
brain. First, we performed immunohistochemistry using antibodies against endostatin, a naturally-occurring C-terminal fragment derived from COL18A1. We found that COL18A1 protein is highly expressed in the pia and blood vessels of postmortem mid-fetal (Fig 2A) and adult (Fig 2B) human cerebral cortex, which is similar to the expression of Col18a1 in the embryonic mouse brain (Fig 2C) .
We then analyzed the spatial and temporal changes in the expression pattern of COL18A1 during human cortical development using the Human Brain Transcriptome database. 21 The Human Brain Transcriptome database is a public database containing genome-wide RNA expression data, and associated metadata set was generated from 1340 tissue samples collected from 16 brain regions including the cerebellar cortex, mediodorsal nucleus of the thalamus, striatum, amygdala, hippocampus, and 11 areas of the neocortex of 57 developing and adult postmortem brains of clinically unremarkable donors representing males and females of multiple ethnicities. The relative levels of RNA expression can be tracked over the course of development. We found that COL18A1 mRNA expression is low-to-moderate (6<log2 intensity<7) in the cortical areas of human brains ( Supplementary Fig 5) . 21 We next performed coexpression analysis 21, 22 on COL18A1 and found that COL18A1 is positively coexpressed with genes known to cause cortical malformation syndromes such as DOCK6 (responsible for Adams-Oliver syndrome 2), LAMC3 (responsible for occipital cortical malformations), and COL6A3 (responsible for Bethlem myopathy) (Supplementary Table 5 ).
Discussion
COL18A1 and Knobloch syndrome
COL18A1 is located on the long arm of chromosome 21 (chr21q22.3) and is composed of 43 exons. It encodes the collagen XVIII protein, which has been revealed to be an important component of basement membranes.
23 COL18A1 has at least three distinct isoforms of different lengths; these isoforms arise through the use of at least two promoters and alternative splicing in the third exon. 24,25b Although COL18A1 is ubiquitously expressed, its isoforms have different tissue and developmental distribution. 7 In addition to these three isoforms, COL18A1 can produce endostatin via proteolytic cleavage. Endostatin is a signaling molecule known to inhibit the migration and proliferation of endothelial cells and is capable of suppressing angiogenesis. 26 Genetic studies have identified exons 30 through 42 of COL18A1 as being the most frequently mutated in Knobloch syndrome patients; however, there remains much heterogeneity in mutation site distribution. 4 Recently, germline
In the mid-fetal (A) and adult (B) human cerebral cortex, COL18A1 protein is expressed in the pia (arrow heads) as well as the blood vessels (arrows). In the mouse embryo (C), mouse Col1Ba1 mRNA is also highly expressed in the pia and blood vessels within the cerebral cortex. Mouse images were obtained from the publicly available Allen Developing Mouse Brain Atlas (http://developingmouse.brain-map.org/). PCW, postconception weeks; E, embryonic day.
Rectangles represent area displayed in magnified panels. (The color version of this figure is available in the online edition.) In our cohort of four patients, who presented with brain malformations, we identified two novel homozygous deleterious mutations and found one mutation that was previously reported 14 dall mutations were located in either the alpha-helix or the endostatin domains of COL18A1 (Fig 1) .
Aside from one patient (NG1348-1) who possesses a nonconserved missense mutation in PCNT, none of the four individuals described in this study possessed any other known disease-causing mutations that may have been responsible for their phenotypes. Patient NG1348-1 displayed none of the characteristic phenotypical findings associated with PCNT mutations (stereotyped facial dysmorphisms, microcephaly, long-bone and/or axial skeleton aberrations, high-pitched voice, microdontia, hyperinsulinism, pigmentation abnormalities, and so forth). 27 Although the mutation in PCNT may be contributing to the phenotype, the clinical presentation of this patient is much more consistent with a Knobloch syndrome diagnosis and suggests that it is the mutation in COL18A1 that is responsible for the observed brain malformations.
Clinical features of Knobloch syndrome
Ocular and occipital skull defects are the two hallmark features of Knobloch syndrome. Ocular defects often appear before 1 year of age and include progressive high myopia, lens subluxation, vitreoretinal degeneration, retinal detachment, and cataracts. 1, 2, 4 All four patients in our cohort were evident to have ocular abnormalities consistent with the Knobloch syndrome phenotype.
Occipital skull defects range from encephaloceles to purely bone lesions to scalp abnormalities such as cutis aplasia.
1,2,4 Studies have found that there is no correlation between the size or the severity of occipital abnormality and the site of the mutation in COL18A1; our findings are consistent with these data. Further, variability in the size of the occipital alteration is commonly observed in both intrafamilial and interfamilial cases, and sometimes, it is noticed only through computed tomographic scan. 2, 7 Interestingly, only one of the four patients in our cohort was evident to have an occipital defect characteristic of the Knobloch syndrome phenotype.
Although both early-onset high myopia and the presence of an occipital skull defect are the two hallmark clinical features of patients with Knobloch syndrome, a spectrum of phenotypic expressions clearly exists. Because of the variable presentation of occipital defects, we can assume that a certain percentage of patients who harbor mutations in COL18A1 will present without any occipital skull abnormalities.
This may explain the lack of occipital skull phenotype in our patients. Further, a number of sporadic Knobloch syndrome patients who present with only ocular defects may go undiagnosed. 9, 28, 29 Given the consanguinity, a second disorder might also be possible although this should have been evident on exome sequencing with homozygous changes.
A recent study by Khan et al. 3 also demonstrated that ophthalmic findings are sufficient to accurately diagnose to Knobloch syndrome. Therefore, an experienced ophthalmologist is capable of properly diagnosing patients with this condition. This highlights the importance of the ocular phenotype and offers further evidence of the phenotypic heterogeneity of this disorder. Interestingly, all our cases have cognitive decline and/or developmental delay, neither of which is common in Knobloch syndrome patients (Table 2) . One possible explanation is previous studies have documented the high rates of concomitant developmental and neurological disability that are associated with structural brain disorders. 30 Severity and types of behavioral and cognitive outcomes of the structural brain disorders seem to be depending on the location of the cortical abnormality. 31 However, we believe that generally a precise diagnostic prediction of abnormalities associated with specific anomalies has not been possible, and this issue requires further studies.
We observed additional aberrations in our patients including atrial septal defects, seizures, and minor dysmorphic findings. These findings highlight the wide phenotypic spectrum that Knobloch syndrome can encompass and also further illustrates the importance of type XVIII collagen in the normal development of multiple organ systems.
Brain malformations in Knobloch syndrome
To date, only four case series describing a total of seven patients reported brain malformations associated with Knobloch syndrome (Table 1) . 3, 9, 10, 14 As with other phenotypic manifestations of Knobloch syndrome, it appears that structural brain abnormalities due to mutations in COL18A1 have marked heterogeneity. An additional possibility is that, because of methodologic limitations, we are failing to detect the other causative variants driving the brain malformation phenotype. Given our findings, we remain confident that mutations in COL18A1 can result in a brain malformation phenotype. The mutations we identified were located in either the alpha-helical or the endostatin domains. It appears that mutations in either of these domains are sufficient to result in a brain malformation phenotype.
Possible role of COL18A1 in human neurodevelopment
Using immunohistochemical and expression analyses we have demonstrated COL18A1 expression in the pia and blood vessels of the developing human cerebral cortex. In C. elegans, inactivation of collagen XVIII results in improper neuronal cell migration. 30 These findings may suggest a potential role for COL18A1 in human neurodevelopment. Furthermore, aberrations in neuronal migration that result from COL18A1 mutations may contribute to the pathogenesis and phenotypes observed in these patients.
Conclusions
We describe a cohort of four patients from four consanguineous families who demonstrated phenotypic characteristics consistent with Knobloch syndrome and who were found to possess mutations in COL18A1 via whole-exome and Sanger sequencing. All these patients presented with various structural brain malformations aside from encephaloceles, an unusual finding for Knobloch syndrome. This study contributes to the reports demonstrating significant clinical variability in Knobloch syndrome while simultaneously highlighting the importance and persistence of the ocular phenotype. Furthermore, our data illustrate the intrafamilial and interfamilial phenotypic heterogeneity that can result from mutations in COL18A1dour genetic analysis and review of previously reported cases demonstrated no specific COL18A1 isoform or mutation effect on the resulting phenotype. This report contributes to a better characterization of the brain malformations associated with deficiency of collagen XVIII, further elucidates potential Knobloch syndrome phenotypes, and suggests a role for COL18A1 in cortical development. Finally, we propose that patients diagnosed with Knobloch syndrome and found to have COL18A1 mutations should be investigated for potential central nervous system lesions.
SUPPLEMENTARY FIGURE 2.
Alignment data for the three index patients analyzed via whole-exome sequencing (NG133-1, NG1348-1, and NG1426-1) demonstrating the identified mutations in COL18A1. The top line in each panel represents the nonmutated reference sequence. The subsequent lines below the reference lines depict the results from exome sequence. Each line represents a distinct coverage read. Mean 20Â coverage of all bases was above 82% for all patients. Each of these mutations induces a frame shift.
